The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-tumor Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cytotoxic Drugs
1.2.3 Non-cytotoxic Drugs
1.3 Market by Application
1.3.1 Global Anti-tumor Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Alkylating Agents
1.3.3 Anti-Metabolism Drugs
1.3.4 Platinum Antineoplastic Agents
1.3.5 Anthracycline Antitumor Drugs
1.3.6 Microtubule Stabilizer
1.3.7 Endocrine Therapy Drugs
1.3.8 Immunotherapy Drugs
1.3.9 Gene Therapy Drugs
1.3.10 Targeted Antineoplastic Drugs
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-tumor Drug Market Perspective (2019-2030)
2.2 Anti-tumor Drug Growth Trends by Region
2.2.1 Global Anti-tumor Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-tumor Drug Historic Market Size by Region (2019-2024)
2.2.3 Anti-tumor Drug Forecasted Market Size by Region (2025-2030)
2.3 Anti-tumor Drug Market Dynamics
2.3.1 Anti-tumor Drug Industry Trends
2.3.2 Anti-tumor Drug Market Drivers
2.3.3 Anti-tumor Drug Market Challenges
2.3.4 Anti-tumor Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-tumor Drug Players by Revenue
3.1.1 Global Top Anti-tumor Drug Players by Revenue (2019-2024)
3.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2019-2024)
3.2 Global Anti-tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-tumor Drug Revenue
3.4 Global Anti-tumor Drug Market Concentration Ratio
3.4.1 Global Anti-tumor Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-tumor Drug Revenue in 2023
3.5 Anti-tumor Drug Key Players Head office and Area Served
3.6 Key Players Anti-tumor Drug Product Solution and Service
3.7 Date of Enter into Anti-tumor Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-tumor Drug Breakdown Data by Type
4.1 Global Anti-tumor Drug Historic Market Size by Type (2019-2024)
4.2 Global Anti-tumor Drug Forecasted Market Size by Type (2025-2030)
5 Anti-tumor Drug Breakdown Data by Application
5.1 Global Anti-tumor Drug Historic Market Size by Application (2019-2024)
5.2 Global Anti-tumor Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-tumor Drug Market Size (2019-2030)
6.2 North America Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-tumor Drug Market Size by Country (2019-2024)
6.4 North America Anti-tumor Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-tumor Drug Market Size (2019-2030)
7.2 Europe Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-tumor Drug Market Size by Country (2019-2024)
7.4 Europe Anti-tumor Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-tumor Drug Market Size (2019-2030)
8.2 Asia-Pacific Anti-tumor Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-tumor Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-tumor Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-tumor Drug Market Size (2019-2030)
9.2 Latin America Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-tumor Drug Market Size by Country (2019-2024)
9.4 Latin America Anti-tumor Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-tumor Drug Market Size (2019-2030)
10.2 Middle East & Africa Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-tumor Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-tumor Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Anti-tumor Drug Introduction
11.1.4 Roche Revenue in Anti-tumor Drug Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Anti-tumor Drug Introduction
11.2.4 Novartis Revenue in Anti-tumor Drug Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Celgene
11.3.1 Celgene Company Detail
11.3.2 Celgene Business Overview
11.3.3 Celgene Anti-tumor Drug Introduction
11.3.4 Celgene Revenue in Anti-tumor Drug Business (2019-2024)
11.3.5 Celgene Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Anti-tumor Drug Introduction
11.4.4 Bristol-Myers Squibb Revenue in Anti-tumor Drug Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Amgen
11.5.1 Amgen Company Detail
11.5.2 Amgen Business Overview
11.5.3 Amgen Anti-tumor Drug Introduction
11.5.4 Amgen Revenue in Anti-tumor Drug Business (2019-2024)
11.5.5 Amgen Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Anti-tumor Drug Introduction
11.6.4 Johnson & Johnson Revenue in Anti-tumor Drug Business (2019-2024)
11.6.5 Johnson & Johnson Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Anti-tumor Drug Introduction
11.7.4 Pfizer Revenue in Anti-tumor Drug Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Takeda
11.8.1 Takeda Company Detail
11.8.2 Takeda Business Overview
11.8.3 Takeda Anti-tumor Drug Introduction
11.8.4 Takeda Revenue in Anti-tumor Drug Business (2019-2024)
11.8.5 Takeda Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Detail
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Anti-tumor Drug Introduction
11.9.4 Eli Lilly Revenue in Anti-tumor Drug Business (2019-2024)
11.9.5 Eli Lilly Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Detail
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Anti-tumor Drug Introduction
11.10.4 AstraZeneca Revenue in Anti-tumor Drug Business (2019-2024)
11.10.5 AstraZeneca Recent Development
11.11 Astellas
11.11.1 Astellas Company Detail
11.11.2 Astellas Business Overview
11.11.3 Astellas Anti-tumor Drug Introduction
11.11.4 Astellas Revenue in Anti-tumor Drug Business (2019-2024)
11.11.5 Astellas Recent Development
11.12 Merck & Co
11.12.1 Merck & Co Company Detail
11.12.2 Merck & Co Business Overview
11.12.3 Merck & Co Anti-tumor Drug Introduction
11.12.4 Merck & Co Revenue in Anti-tumor Drug Business (2019-2024)
11.12.5 Merck & Co Recent Development
11.13 Sanofi
11.13.1 Sanofi Company Detail
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Anti-tumor Drug Introduction
11.13.4 Sanofi Revenue in Anti-tumor Drug Business (2019-2024)
11.13.5 Sanofi Recent Development
11.14 Bayer
11.14.1 Bayer Company Detail
11.14.2 Bayer Business Overview
11.14.3 Bayer Anti-tumor Drug Introduction
11.14.4 Bayer Revenue in Anti-tumor Drug Business (2019-2024)
11.14.5 Bayer Recent Development
11.15 Biogen Idec
11.15.1 Biogen Idec Company Detail
11.15.2 Biogen Idec Business Overview
11.15.3 Biogen Idec Anti-tumor Drug Introduction
11.15.4 Biogen Idec Revenue in Anti-tumor Drug Business (2019-2024)
11.15.5 Biogen Idec Recent Development
11.16 Eisai
11.16.1 Eisai Company Detail
11.16.2 Eisai Business Overview
11.16.3 Eisai Anti-tumor Drug Introduction
11.16.4 Eisai Revenue in Anti-tumor Drug Business (2019-2024)
11.16.5 Eisai Recent Development
11.17 Teva
11.17.1 Teva Company Detail
11.17.2 Teva Business Overview
11.17.3 Teva Anti-tumor Drug Introduction
11.17.4 Teva Revenue in Anti-tumor Drug Business (2019-2024)
11.17.5 Teva Recent Development
11.18 Otsuka
11.18.1 Otsuka Company Detail
11.18.2 Otsuka Business Overview
11.18.3 Otsuka Anti-tumor Drug Introduction
11.18.4 Otsuka Revenue in Anti-tumor Drug Business (2019-2024)
11.18.5 Otsuka Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details